This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hambleton, S.
Right arrow Articles by Gershon, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hambleton, S.
Right arrow Articles by Gershon, A. A.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, January 2005, p. 70-80, Vol. 18, No. 1
0893-8512/05/$08.00+0     doi:10.1128/CMR.18.1.70-80.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Preventing Varicella-Zoster Disease

Sophie Hambleton and Anne A. Gershon*

Department of Pediatrics, Columbia University College of Physicians & Surgeons, New York, New York

Varicella-zoster virus (VZV), the cause of chickenpox and shingles, is a pathogen in retreat following the introduction of mass vaccination in the United States in 1995. The live attenuated Oka vaccine, which is safe and immunogenic, gives good protection against both varicella and zoster in the short to medium term. It has undoubtedly been highly effective to date in reducing all forms of varicella, especially severe disease. However, the huge pool of latent wild-type virus in the population represents a continuing threat. Both the biology and the epidemiology of VZV disease suggest that new vaccination strategies will be required over time.

* Corresponding author. Mailing address: Columbia University College of Physicians & Surgeons, 650 W. 168th Street, New York, NY 10032. Phone: (212) 305-9445. Fax: (212) 342-5218. E-mail: aag1{at}columbia.edu.

Clinical Microbiology Reviews, January 2005, p. 70-80, Vol. 18, No. 1
0893-8512/05/$08.00+0     doi:10.1128/CMR.18.1.70-80.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Chanan-Khan, A., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., Neuwirth, R., Anderson, K. C., Richardson, P. G. (2008). Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study. JCO 26: 4784-4790 [Abstract] [Full Text]  
  • Snape, M D, Kelly, D F, Lewis, S, Banner, C, Kibwana, L, Moore, C E, Diggle, L, John, T, Yu, L M, Borrow, R, Borkowski, A, Nau, C, Pollard, A J (2008). Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 336: 1487-1491 [Abstract] [Full Text]  
  • Gershon, A. A. (2008). Varicella-Zoster Virus Infections. Pediatr. Rev. 29: 5-11 [Full Text]  
  • Zhang, Z., Rowe, J., Wang, W., Sommer, M., Arvin, A., Moffat, J., Zhu, H. (2007). Genetic Analysis of Varicella-Zoster Virus ORF0 to ORF4 by Use of a Novel Luciferase Bacterial Artificial Chromosome System. J. Virol. 81: 9024-9033 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»